Q3 EPS Estimate for Keros Therapeutics Lowered by Analyst

Key Points

• William Blair has revised its Q3 2025 EPS forecast for Keros Therapeutics from ($0.83) to ($1.03), while also predicting lower earnings for subsequent quarters and years.
• The company reported a quarterly EPS of ($0.76), beating expectations, but revenue significantly underperformed at $0.02 million against an estimated $3.83 million.
• Analysts have downgraded Keros Therapeutics' stock ratings, with price targets decreasing significantly from previous forecasts, reflecting a more cautious outlook on the company’s performance.

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Research analysts at William Blair cut their Q3 2025 EPS estimates for shares of Keros Therapeutics in a note issued to investors on Wednesday, August 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($1.03) for the quarter, down from their prior forecast of ($0.83). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics' Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at $0.82 EPS, Q1 2026 earnings at ($1.17) EPS, Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($4.77) EPS, FY2027 earnings at ($4.48) EPS and FY2028 earnings at ($3.95) EPS.

Other research analysts also recently issued research reports about the stock. Wedbush restated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Friday, May 30th. Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank dropped their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Finally, HC Wainwright dropped their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock traded up $0.32 during midday trading on Monday, reaching $14.28. 109,065 shares of the company's stock traded hands, compared to its average volume of 990,366. The company has a market cap of $580.05 million, a price-to-earnings ratio of 45.90, a price-to-earnings-growth ratio of 1.68 and a beta of 1.33. The company's 50 day simple moving average is $13.96 and its 200 day simple moving average is $12.82. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. Keros Therapeutics's revenue for the quarter was up 49002.7% on a year-over-year basis. During the same quarter last year, the firm earned ($1.25) EPS.

Institutional Trading of Keros Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Corebridge Financial Inc. grew its position in Keros Therapeutics by 6.4% in the 1st quarter. Corebridge Financial Inc. now owns 16,212 shares of the company's stock worth $165,000 after purchasing an additional 972 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Keros Therapeutics by 6.0% during the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock valued at $286,000 after acquiring an additional 1,027 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Keros Therapeutics by 7.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock valued at $303,000 after acquiring an additional 1,386 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after acquiring an additional 1,892 shares in the last quarter. Finally, Virtus ETF Advisers LLC boosted its position in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.